СУРУНКАЛИ ГЕНЕРАЛЛАШГАН ПАРОДОНТИТ БИЛАН ОҒРИГАН БЕМОРЛАРДА БУЙРАК ШИКАСТЛАНИШИНИНГ БИОМАРКЕРЛАРИ, СЎЛАК, ҚОН ВА СИЙДИКДАГИ ЎЗГАРИШЛАРИ
##article.subject##:
буйрак трансплантацияси, гипероксалурия, уратурия, сурункали буйрак етишмовчилиги, сурункали генераллашган пародонтит##article.abstract##
Сурункали пиелонефрит билан оғриган 33 бемор ва 40 нафар деярли соғлом шахсларни клиник кузатиш ва текшириш ўтказилди. CП билан оғриган беморлар икки марта текширилди. Биринчи гуруҳга (ГI гуруҳ) ушбу касалликнинг кучайиши билан оғриган беморлар киритилган. Таққослаш гуруҳида (ГII), худди шу беморлар даволаниш тугаганидан 1,5-3 ой ўтгач, СП кучайишининг клиник кўринишисиз. Барча текширилган беморларда буйракнинг ўткир шикастланишининг лаборатория белгилари аниқланмади. Сийдикдаги VEGF, МСР-1, ИЛ-8 ва ИЛ-18 концентрацияси барча текширилган шахсларнинг сийдик намуналарида ИФА усули билан аниқланди. Сийдикнинг оқсил спектри 6 ГI и 6 ГII беморларида Agilent 1100 хроматографи ёрдамида масс-спектрометрик таҳлил ёрдамида ўрганилди. Сийдик оқсилларини икки усул билан параллел равишда аниқлаш натижалари шуни кўрсатдики, CП нингкучайиши буйрак тубулалари уротелияси даражасида маҳаллий иккиламчи иммунитет етишмовчилиги фонида ривожланади.
Библиографические ссылки
Rytikova N.S., Smirnova M.A., Ugol’kova N.V. et al. Study of renal function. Katalog BioKhimMak, 2007, vol. 2, no. 4, pp. 594-597 (in Russ.).
Belokhvostikova T.S., Orlova G.M., Fatakhova O.A et al. Lipokain associated with neutrophil gelatinase, in patients with chronic kidney disease: clinical and laboratory relationship. Nefrologiya i dializ, 2011, vol. 13, no. 3, pp. 268-369 (in Russ.).
Belokhvostikova T.S. et al. Lipokalin, assotsiirovannyy s zhelatinazoy neytrofilov, u bol’nykh khronicheskoy bolezn’yu pochek: kliniko-laboratornye vzaimosvyazi [Lipocalin associated with neutrophil gelatinase, in patients with chronic kidney disease: clinical and laboratory relationship]. Nefrologiya i gemodializ. Materialy VII konferentsii RDO, 2011. Vol. 13, no. 3, pp. 268-269.
Proletov Ya.Yu., Saganova E.S., Galkina O.V. The role of some biomarkers in assessing the nature of chronic renal damage in patients with primary glomerulopathy. Nefrologiya, 2013, no. 1, pp. 60-69 (in Russ.).
Arutyunov G.P., Oganezova L.G., Sokolova A.V. Experimental models of renal tissue destruction tubulointersticial hypertension. Klinicheskaya nefrologiya, 2011, no. 2, pp. 75-78 (in Russ.).
Kuwabara T., Mori K., Mukoyama M. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int., 2009, vol. 75, no. 3, pp. 285-294.
Shen S.J., Hu Z.X., Li Q.H. Implications of the changes in serum neutrophil gelatinase-associated lipocalin and cystatin C in patients with chronic kidney disease. Nephrology (Carlton), 2014, vol. 19, no. 3, pp. 29-35.
Prkacin I., Ozvald I., Cavrić G., Balenović D., Bulum T., Flegar-Mestrić Z. Importance of urinary NGAL, serum creatinine standardization and estimated glomerular filtration rate in resistant hypertension. Coll. Antropol., 2013, vol. 37, no. 3, pp. 7821-7825.
Mori K., Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int., 2007, vol. 71, no. 10, pp. 967-970.
Damman K., Van Veldhuisen D.J., Navis G. et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart, 2010, no. 96, pp. 1297-1302.
Kamijo-Ikemori A., Ichikawa D., Matsui K., Yokoyama T., Sugaya T., Kimura K. Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan. Rinsho Byori., 2013, vol. 96, no. 61, pp. 635-640.
Ichimura et al. Kidney injury molecule-1 (KIM-1), a putativeepithelial cell adhesion molecule containing a novel immunoglobylindomain, is up-regulated in renal cells after injury. J. Biol. Chem., 1998, vol. 273, no. 7, pp. 4135-4142.
Vaidya V.S., Bobadila N.A., Bonventre J.V. Urinary kidney injury molecule – 1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal. Physiol., 2006, vol. 290, no. 2, pp. 517-529.
Vaidya V.S., Ford G.M., Waikar S.S. et al. A rapid urine test for early detection of kidney injury. Kidney Int., 2009, vol. 76, no. 1, pp. 108-114.
15 Han W.K., Bailly V., Bonventre J.V. Kidney injury molecule – 1(KIM-1): a novel biomarker for human renal proximal tubular injury. Kidney Intern., 2002, vol. 62, no. 1, pp. 237-244.
K/DOQI Clinical practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am. J. Kidney Dis., 2003, vol. 41 (suppl. 4), pp. 91-92.
Liangos O., Perianayagam M.C., Vaidya V.S. et al. Urinary N-acetyl-β(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J. Am. Soc. Nephrol., 2007, vol. 18, no. 3, pp. 904-912.
Szeto C.C., Kwan B.C., Lai K. B. et al. Urinary expression of kidney injury markers in renal transplant recipients. Clin. J. Am. Soc. Nephrol., 2010, vol. 4, no. 12, pp. 2329-2337.
Femke Waanders M.D. et al. Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled Trial. Am. J. Kidney Dis., 2009, vol. 53, no. 1, pp. 16-25.
Jungbauer C.G., Birner C., Jung B., Buchner S., Lubnow M., von Bary C., Endemann D., Banas B., Mack M., Böger C.A., Riegger G., Luchner A. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur. J. Heart Fail., 2011, vol. 13, no. 10, pp. 1104-1110.
Damman K., Masson S., Hillege H.L. et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail., 2013, vol. 1, no. 5, pp. 417-424.
Tomanek R.J., Holifield J.S., Reiter R.S. et al. Role of VEGF family members and receptors in coronary vessel formation. Dev. Dyn., 2002, vol. 225, pp. 233-240.
Trape J.C., Morales R., Molina X. et al. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scand. J. Clin. Lab. Invest., 2006, vol. 663, pp. 261-267.
Nanchikeeva M.L. Rannyaya stadiya porazheniya pochek u bol’nykh gipertonicheskoy bolezn’yu: klinicheskoe znachenie, printsipy profilaktiki: avtoref. dis. … d-ra med. nauk [Early-stage renal disease in patients with hypertension: clinical significance, the principles of prevention. Synopsis of dis. Dr med. sci]. Moscow, 2010.
Ayerden Ebinz F., Haksun E., Ulver D.B. et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern. Med., 2008, vol. 47, no. 17, pp.1511-1516. .
Kubisz P., Chude P., Stasko J. et al. Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus. Act. Diabetol., 2010, vol. 47, no. 2, pp. 119-124
Loebig M., Klement J., Schmoller A. et al. Evidence for a relationship between vegf and bmi independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men. PLoS One, 2010, vol. 7, no. 5, pp. 145-152.
Chung N.A., Beevers D.G., Lip G. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood. Press., 2004, vol. 13, no. 3, pp. 183-189.
Bobkova I.N. Clinical significance of determination of urinary markers of endothelial dysfunction and angiogenesis factors in the evaluation of tubulointerstitial fibrosis in chronic glomerulonephritis. Terapevticheskiy arkhiv, 2007, no. 6, pp. 10-15 (in Russ.).
Morozov D.A., Morrison V.V., Morozova O.L. Pathogenetic bases and modern possibilities of early diagnosis of nephrosclerosis in children with vesicoureteral reflux. Saratovskiy nauchno-meditsinskiy zhurnal, 2011, vol. 7, no. 1, pp. 151-157 (in Russ.).
